Platelet reactivity when switching from cangrelor to oral P2Y12 receptor inhibitors: insights from a real-world registry.
作者信息
Franchi Francesco, Laudani Claudio
机构信息
Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL, USA.
Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "Rodolico - San Marco", University of Catania, Catania, Italy.
出版信息
EuroIntervention. 2025 May 16;21(10):497-499. doi: 10.4244/EIJ-E-25-00008.
Abstract
摘要
相似文献
1
Platelet reactivity when switching from cangrelor to oral P2Y12 receptor inhibitors: insights from a real-world registry.从坎格雷洛转换为口服P2Y12受体抑制剂时的血小板反应性：来自真实世界注册研究的见解
EuroIntervention. 2025 May 16;21(10):497-499. doi: 10.4244/EIJ-E-25-00008.
2
Pharmacodynamic effects of cangrelor in patients with acute or chronic coronary syndrome undergoing percutaneous coronary intervention: the POMPEII Registry.坎格雷洛在接受经皮冠状动脉介入治疗的急性或慢性冠状动脉综合征患者中的药效学效应：庞贝城登记研究
EuroIntervention. 2025 May 16;21(10):560-570. doi: 10.4244/EIJ-D-24-00757.
3
Switching from cangrelor to oral P2Y inhibitors: a focused review on drug-drug interactions.从坎格雷洛转换为口服P2Y抑制剂：关于药物相互作用的重点综述
Expert Opin Drug Metab Toxicol. 2025 Jan;21(1):29-40. doi: 10.1080/17425255.2024.2418033. Epub 2024 Oct 20.
4
Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor.网织血小板对静脉注射 P2Y12 受体抑制剂坎格雷洛抗血小板作用的影响。
Thromb Haemost. 2018 Feb;118(2):362-368. doi: 10.1160/TH17-07-0466. Epub 2018 Jan 29.
5
Periprocedural platelet inhibition with cangrelor in P2Y-inhibitor naïve patients with acute coronary syndromes - A matched-control pharmacodynamic comparison in real-world patients.在未使用P2Y抑制剂的急性冠状动脉综合征患者中使用坎格雷洛进行围手术期血小板抑制——真实世界患者的配对对照药效学比较
Int J Cardiol. 2016 Nov 15;223:848-851. doi: 10.1016/j.ijcard.2016.08.270. Epub 2016 Aug 17.
6
Combining the P2Y antagonist cangrelor with energy metabolism inhibitors has a synergistic antiaggregatory effect.将P2Y拮抗剂坎格雷洛与能量代谢抑制剂联合使用具有协同抗聚集作用。
Biochem Pharmacol. 2025 Oct;240:117056. doi: 10.1016/j.bcp.2025.117056. Epub 2025 Jun 24.
7
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.在接受直接经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者中，用坎格瑞洛和替卡格雷洛进行血小板抑制。
Circulation. 2019 Apr 2;139(14):1661-1670. doi: 10.1161/CIRCULATIONAHA.118.038317.
8
Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists.从坎格雷洛转换为口服血小板P2Y12受体拮抗剂的过渡策略。
Coron Artery Dis. 2016 Jan;27(1):65-9. doi: 10.1097/MCA.0000000000000311.
9
Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction.在现实世界中患有ST段抬高型心肌梗死的患者进行直接经皮冠状动脉介入治疗期间及之后，坎格雷洛与替格瑞洛联合使用可提供持续且强效的P2Y12抑制作用。
Platelets. 2017 Jun;28(4):414-416. doi: 10.1080/09537104.2016.1246714. Epub 2016 Nov 25.
10
A Safety Evaluation of Cangrelor in Patients Undergoing PCI.坎格雷洛在接受经皮冠状动脉介入治疗患者中的安全性评估。
Expert Opin Drug Saf. 2016;15(2):275-85. doi: 10.1517/14740338.2016.1133585. Epub 2016 Jan 9.
本文引用的文献
1
International Consensus Statement on Platelet Function and Genetic Testing in Percutaneous Coronary Intervention: 2024 Update.国际经皮冠状动脉介入治疗血小板功能与基因检测共识声明：2024 更新版。
JACC Cardiovasc Interv. 2024 Nov 25;17(22):2639-2663. doi: 10.1016/j.jcin.2024.08.027.
2
Downstream cangrelor versus upstream ticagrelor in patients with ST-segment elevation myocardial infarction: A propensity score-matched analysis.依替巴肽与替格瑞洛在 ST 段抬高型心肌梗死患者中的疗效比较：倾向评分匹配分析。
Int J Cardiol. 2025 Jan 1;418:132660. doi: 10.1016/j.ijcard.2024.132660. Epub 2024 Oct 18.
3
2023 ESC Guidelines for the management of acute coronary syndromes.2023年欧洲心脏病学会急性冠状动脉综合征管理指南。
Eur Heart J. 2023 Oct 12;44(38):3720-3826. doi: 10.1093/eurheartj/ehad191.
4
Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet-6 (SWAP-6) Study.经皮冠状动脉介入治疗患者由坎格瑞洛转换为普拉格雷：SWAP-6 研究。
JACC Cardiovasc Interv. 2023 Oct 23;16(20):2528-2539. doi: 10.1016/j.jcin.2023.08.009. Epub 2023 Aug 21.
5
Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor: The Switching Antiplatelet (SWAP)-5 Study.替格瑞洛预处理的冠心病患者中使用坎格雷洛：转换抗血小板（SWAP）-5研究
JACC Cardiovasc Interv. 2023 Jan 9;16(1):36-46. doi: 10.1016/j.jcin.2022.10.034. Epub 2022 Oct 31.
6
Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial.替格瑞洛、替罗非班和嚼碎或标准普拉格雷方案在 ST 段抬高型心肌梗死患者中的应用：FABOLUS-FASTER 试验的主要结果。
Circulation. 2020 Aug 4;142(5):441-454. doi: 10.1161/CIRCULATIONAHA.120.046928. Epub 2020 Jun 27.
7
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.在接受直接经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者中，用坎格瑞洛和替卡格雷洛进行血小板抑制。
Circulation. 2019 Apr 2;139(14):1661-1670. doi: 10.1161/CIRCULATIONAHA.118.038317.
8
International Expert Consensus on Switching Platelet P2Y Receptor-Inhibiting Therapies.国际血小板 P2Y 受体抑制剂转换治疗专家共识。
Circulation. 2017 Nov 14;136(20):1955-1975. doi: 10.1161/CIRCULATIONAHA.117.031164. Epub 2017 Oct 30.
9
A Safety Evaluation of Cangrelor in Patients Undergoing PCI.坎格雷洛在接受经皮冠状动脉介入治疗患者中的安全性评估。
Expert Opin Drug Saf. 2016;15(2):275-85. doi: 10.1517/14740338.2016.1133585. Epub 2016 Jan 9.
10
Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data.坎格雷洛对经皮冠状动脉介入治疗围术期结局的影响：患者水平数据的汇总分析。
Lancet. 2013 Dec 14;382(9909):1981-92. doi: 10.1016/S0140-6736(13)61615-3. Epub 2013 Sep 3.
Zotero 插件